UBS Group Cuts Becton Dickinson and (BDX) Price Target to $250.00

Becton Dickinson and (NYSE:BDX) had its price target lowered by UBS Group from $265.00 to $250.00 in a research report released on Friday, BenzingaRatingsTable reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

A number of other research analysts also recently weighed in on BDX. Zacks Investment Research raised shares of Becton Dickinson and from a sell rating to a hold rating in a research report on Wednesday, April 10th. ValuEngine downgraded shares of Becton Dickinson and from a buy rating to a hold rating in a research report on Monday, April 1st. Piper Jaffray Companies raised their target price on shares of Becton Dickinson and to $274.00 and gave the company an overweight rating in a research report on Tuesday, February 5th. KeyCorp reaffirmed an overweight rating and issued a $262.00 target price (down previously from $273.00) on shares of Becton Dickinson and in a research report on Friday. Finally, Barclays raised their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an equal weight rating in a research report on Monday, April 15th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and presently has an average rating of Buy and an average target price of $256.46.

Shares of BDX stock traded down $4.40 during trading hours on Friday, hitting $225.40. 2,481,356 shares of the company were exchanged, compared to its average volume of 1,638,749. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. Becton Dickinson and has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a market capitalization of $61.83 billion, a price-to-earnings ratio of 20.47, a P/E/G ratio of 1.67 and a beta of 1.16.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter in the prior year, the firm earned $2.65 earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. On average, equities analysts expect that Becton Dickinson and will post 11.74 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 4,808 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $1,226,184.24. Following the completion of the sale, the executive vice president now owns 22,476 shares in the company, valued at $5,732,054.28. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 8,309 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the completion of the sale, the chief executive officer now owns 222,785 shares of the company’s stock, valued at approximately $56,839,137.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,684 shares of company stock valued at $7,518,574. 0.12% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. Charter Trust Co. lifted its stake in shares of Becton Dickinson and by 0.9% during the 1st quarter. Charter Trust Co. now owns 13,372 shares of the medical instruments supplier’s stock worth $3,339,000 after buying an additional 120 shares during the last quarter. King Luther Capital Management Corp lifted its stake in shares of Becton Dickinson and by 28.0% during the 1st quarter. King Luther Capital Management Corp now owns 159,166 shares of the medical instruments supplier’s stock worth $39,749,000 after buying an additional 34,840 shares during the last quarter. AlphaCrest Capital Management LLC lifted its stake in shares of Becton Dickinson and by 192.2% during the 1st quarter. AlphaCrest Capital Management LLC now owns 12,523 shares of the medical instruments supplier’s stock worth $3,127,000 after buying an additional 8,237 shares during the last quarter. Campbell & CO Investment Adviser LLC lifted its stake in shares of Becton Dickinson and by 397.4% during the 1st quarter. Campbell & CO Investment Adviser LLC now owns 5,073 shares of the medical instruments supplier’s stock worth $1,267,000 after buying an additional 4,053 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of Becton Dickinson and by 3.7% during the 1st quarter. Rockefeller Capital Management L.P. now owns 415,937 shares of the medical instruments supplier’s stock worth $103,872,000 after buying an additional 14,896 shares during the last quarter. Hedge funds and other institutional investors own 84.96% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is an overbought condition?

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.